Farxiga DAPA-CKD Phase III trial reduced worsening of kidney function, risk of cardiovascular or renal death in patients with chronic kidney disease, irrespective of underlying cause
Results reinforce Farxiga’s potential to treat a wide range of patients with chronic kidney diseaseA new subgroup analysis from the ground-breaking DAPA-CKD Phase III trial showed that AstraZeneca’s Farxiga (dapagliflozin), on top of standard of care, reduced the composite of worsening of kidney function or risk of cardiovascular (CV) or renal death in patients with chronic kidney disease (CKD), irrespective of the underlying cause of the disease.[1] CKD is a serious, progressive condition defined by decreased kidney function.[2] It is estimated to affect nearly 700 million people